BLUEBONNET: Phase II Study of Nivolumab in combination with Relatlimab in Patients with Active Melanoma Brain Metastases

Lignende værker

• BLUEBONNET: Phase II Study of Nivolumab in combination with Relatlimab in Patients with Active Melanoma Brain Metastases
  af: E. Burton, et al.
  Udgivet: (2026-01-01)
• Correction: Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
  Udgivet: (2020-10-01)
• Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients
  af: Nuri Karadurmus, et al.
  Udgivet: (2018-12-01)
• Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol
  af: J. C. Janssen, et al.
  Udgivet: (2024-05-01)
• Complete Response to Nivolumab‐Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First‐Line Nivolumab‐Ipilimumab: A Case Report
  af: Reema Patel, et al.
  Udgivet: (2026-04-01)